Last updated: 2026-10-19 16:06:00. Prices reflect the latest regular market data. Stock price data is sourced from Massive.
Schrodinger, Inc. (SDGR) operates in the PHARMACEUTICAL PREPARATIONS sector and is listed on NASDAQ. The stock is currently priced at $23.04, with a market capitalization of $1.69B and a P/E ratio of --. Over the past 52 weeks, its price has ranged from $10.95 to $33.78. This page covers its latest market performance, valuation, price trends and company information.
$1.69B | |
$22.85 | |
$117.00 | |
$10.95 | |
$22.60 | |
510.37K | |
1.89M | |
-- | |
$33.78 | |
$10.95 | |
-- | |
-- |
Schrodinger, Inc. (SDGR) is currently trading at $23.04 as of 2026-10-19 15:50:38, up 1.92% ($0.43) from the previous close of $22.60
During today's regular trading session, SDGR has traded between $10.95 and $117.00, with a trading volume of 510.37K shares. The current price is near the lower end of today's range.
Over the past seven days, Schrodinger, Inc. (SDGR) moved from $26.39 to $23.04, representing a decline of 12.71% ($3.36).
The stock traded between $22.56 and $28.16 during the period. The latest price is near the lower end of the 7-day range, indicating strong downward.
The average daily volume was 2.14 million shares, down versus the previous seven-day period, indicating lower trading activity.
Position in Range: 52.9%
SDGR is currently trading at $23.04, placing it 52.9% of the way from its 52-week low of $10.95 to its 52-week high of $33.78. This percentage reflects the stock's relative position within its 52-week trading range, not its valuation or future performance.
Schrodinger Inc is a healthcare-based software company. It offers software solutions designed to support and accelerate the discovery, design, and optimization of molecules. The company operates in two reportable segments: Software and Drug Discovery. The software segment is focused on selling software to transform drug discovery across the life sciences industry, as well as to customers in materials science industries. The drug discovery segment is focused on generating revenue from a diverse portfolio of preclinical and clinical programs, internally and through collaborations, that have various stages of discovery and development. The majority of the company's revenue is derived from the Software segment. Geographically, it derives the maximum revenue from the United States.
| Industry | PHARMACEUTICAL PREPARATIONS |
| Employees | 850 |
| Exchange | NASDAQ |
| Company Website |
Eligible investors can buy real shares of Schrodinger, Inc. (SDGR) through MEXC RealStocks. Follow these three steps to open a RealStocks account, transfer USDT, and place a US stock order.